Back to top

Arcturus Therapeutics: Buy Rating Backed by Advancing mRNA Programs and De-Risked CF Manufacturing Partnership

Analyst Thomas Shrader of BTIG maintained a Buy rating on Arcturus Therapeutics, with a price target of $23.00. Thomas Shrader has given his Buy ra...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Arcturus Therapeutics Holdings Inc. (ARCT)